Cancer and COVID-19: Resources for Patients and Survivors

Preparing for Your Next Clinic Visit

Dr. Marshall explains procedures MedStar and Georgetown have instituted to ensure your safety while you receive the best care possible

View Q&A with Dr. Marshall

Current Clinical Trials

Search our current GI clinical trials offered through the MedStar Georgetown Cancer Institute

View Clinical Trials

New Colon Cancer Concerns

Dr. Marshall talks with Today Show about why colon cancer is on the rise in young patients

View Today Show Segment with Dr. Marshall

2020 Ruesch Center Classic Golf Tournament

Learn more about this year’s event on Monday, August 10, 2020

More information

Dr. John L. Marshall addresses some of the questions he and his Georgetown Lombardi colleagues have been hearing most often from current cancer patients and survivors. Learn More

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.




FDA Approves Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma

March 19th, 2020

“The approval of nivolumab and ipilimumab in the second-line treatment of advanced HCC means we will have a combination immune therapy option in patients who have progressed on frontline therapy. The overall survival (OS) of nivolumab and ipilimumab in the second-line treatment of advanced HCC as shown in CheckMate-040 was very promising, so far the longest duration of OS in the second-line setting for advanced-stage HCC, tested in clinical trials,” said Aiwu Ruth He, MD, PhD, associate professor of Medical Oncology at Georgetown University.

Targeted Therapies Showing Promise in Colorectal Cancer

February 6th, 2020

Benjamin Weinberg, MD, assistant professor of medicine and attending physician at MedStar Georgetown University Hospital, Washington, DC, discusses novel agents that may impact the treatment landscape for colorectal cancer (CRC) once made available in the community setting.



Sign Up to receive all Ruesch updates directly in your Inbox

We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.